semaglutide 7.2 mg clinical trial Efficacy and safety of once-weekly 2·0 versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B Once-weekly semaglutide 7·2 mg in

Response-Based Approach: Treatment duration is individualized based on objective measurements including body composition analysis (DEXA scan, bioimpedance), waist circumference, metabolic markers, and subjective response

4.6.2 Retinal disease Diabetic retinopathy (DR) is the most prevalent microvascular complication of diabetes and the leading cause of preventable blindness among working-age individuals (81)

The gut as a sensory organ

THERAPY NAD+ & NR IV Drips Targeted NAD+ IV therapies designed to enhance cellular energy, mental clarity, metabolic function, and overall vitality

This engine uses high octane for real performance

Our Red Light and Near Infrared (NIR) Therapy offers a non-invasive solution to enhance fat loss , reduce inflammation , and promote skin rejuvenation